---
layout: post
title: "Promoting Effective Drug Development: Identifying Opportunities and Priorities for the Food and Drug Administration's Office of Clinical Pharmacology; Request for Comments"
date: 2026-02-05 19:09:20 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-08956
original_published: 2024-04-26 00:00:00 +0000
significance: 8.00
---

# Promoting Effective Drug Development: Identifying Opportunities and Priorities for the Food and Drug Administration's Office of Clinical Pharmacology; Request for Comments

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 26, 2024 00:00 UTC
**Document Number:** 2024-08956

## Summary

The Food and Drug Administration (FDA or Agency) is establishing a public docket entitled "Promoting Effective Drug Development: Identifying Opportunities and Priorities for the Food and Drug Administration's Office of Clinical Pharmacology." The purpose of this docket is to solicit input from interested parties on specific and actionable policy topics that could be prioritized, developed, and implemented by the staff of the Center for Drug Evaluation and Research's (CDER's) Office of Clinical Pharmacology (OCP) to support effective drug development programs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/04/26/2024-08956/promoting-effective-drug-development-identifying-opportunities-and-priorities-for-the-food-and-drug)
- API: https://www.federalregister.gov/api/v1/documents/2024-08956

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
